{
    "ticker": "CRTD",
    "name": "Cortexyme, Inc.",
    "description": "Cortexyme, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. Founded in 2015 and headquartered in South San Francisco, California, Cortexyme aims to address the underlying causes of neurodegeneration by targeting the bacteria associated with these conditions. The company is known for its lead product candidate, atuzaginstat (COR388), which is designed to inhibit the activity of a specific pathogen believed to play a role in the progression of Alzheimer's. Cortexyme is committed to advancing scientific research and developing effective treatments that can improve the quality of life for patients and their families. The company collaborates with leading academic and research institutions to further its mission of combating neurodegenerative diseases. Cortexyme's innovative approach, rooted in a deep understanding of the complex biology of neurodegeneration, positions it as a potential leader in the biopharmaceutical industry, particularly as the demand for effective Alzheimer's therapies continues to grow. With a strong pipeline of product candidates, Cortexyme is dedicated to making a meaningful impact in the field of neurology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2015",
    "website": "https://www.cortexyme.com",
    "ceo": "Brian C. McGowan",
    "social_media": {
        "twitter": "https://twitter.com/Cortexyme",
        "linkedin": "https://www.linkedin.com/company/cortexyme/"
    },
    "investor_relations": "https://www.cortexyme.com/investors",
    "key_executives": [
        {
            "name": "Brian C. McGowan",
            "position": "CEO"
        },
        {
            "name": "M. Scott Whitcup",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Atuzaginstat (COR388)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Cortexyme, Inc. | Pioneering Therapies for Neurodegenerative Diseases",
        "meta_description": "Learn about Cortexyme, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases like Alzheimer's.",
        "keywords": [
            "Cortexyme",
            "Alzheimer's Disease",
            "Neurodegenerative Diseases",
            "Biopharmaceuticals",
            "COR388"
        ]
    },
    "faq": [
        {
            "question": "What is Cortexyme known for?",
            "answer": "Cortexyme is known for developing therapies targeting the underlying causes of Alzheimer's disease."
        },
        {
            "question": "Who is the CEO of Cortexyme?",
            "answer": "Brian C. McGowan is the CEO of Cortexyme, Inc."
        },
        {
            "question": "Where is Cortexyme headquartered?",
            "answer": "Cortexyme is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What is Cortexyme's main product?",
            "answer": "Cortexyme's main product candidate is atuzaginstat (COR388), aimed at treating Alzheimer's disease."
        },
        {
            "question": "When was Cortexyme founded?",
            "answer": "Cortexyme was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "BIIB",
        "SNY",
        "VRTX"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "GILD"
    ]
}